

Samarpan Majumder, Ph.D.
Assistant Professor, Research

Education

University of Calcutta, India	B.S.	1988	Chemistry (major)
University of Calcutta, India	M.S.	1991	Biochemistry
Bose Institute /University of Calcutta, India	Ph.D.	2000	Biochemistry & Molecular Biology
University of North Carolina at Chapel Hill, Chapel Hill, USA	Postdoctoral Researcher	1998-2002	DNA recombination and repair Biochemistry



Dr. Majumder joined the Department of Genetics at LSU Health New Orleans in November 2017 after spending 20 years in academia and biotech industries. Dr. Majumder received his postdoctoral training in the University of North Carolina (UNC) at Chapel Hill and worked in the field of *Drosophila* genetics. He was instrumental in finding a novel gene in fruit flies, *Drosophila*, that is involved in nucleotide excision repair.

In 2003, he joined Lineberger Comprehensive Research Center in UNC, Chapel Hill and worked in prostate cancer research. While working in this field, he documented the importance of breast cancer gene, *her2*, in the late stage of prostate cancer progression. From 2006 to 2009, he worked in the Department of Pharmacology in UNC and was actively involved in National Institute of Mental Health's (NIMH) psychoactive drug discovery program. He collaborated with University of Wisconsin at Milwaukee and screened compounds that resulted in five peer reviewed publications and compounds with high therapeutic potentials.

While with Vascular Pharmaceuticals, he was responsible in guiding Vascular's day to day research activities comprising of a team of three researchers in their effort to design, develop and commercialize a novel antibody against diabetes accelerated heart complications. Dr. Majumder also worked as a senior scientist with Novametics, where he led the company's efforts to develop and commercialize a novel diagnostic kit to detect blood clotting disorders.

Research Interests

Dr. Majumder has been working to bolster the LSU LCMC Health Cancer Center's breast cancer research program. He brings with him his valuable experience in industry and his previous translational research experience in cancer to integrate and navigate ongoing breast cancer research projects. As an investigator, his focus is on estrogen receptor positive (ER+) endocrine therapy resistant breast cancer. His other active research of interest is to gain insight into the role of gut microbiome in triple-negative breast cancer (TNBC), especially in obese

African American women. He is an expert in the field of preclinical model of cancer, cancer immunotherapy, tumor microenvironment, cancer stem cells and exosomes.